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ABSTRACT

The aim of the current study was to prepare and compare acyclovir (ACV) floating
gastro-retentive formulations synthesized via hot-melt extrusion (HME) techniques using
P-CO2 and sodium bicarbonate. Physical mixtures of ACV (20%, w/w) and HPC EF (70%,
60%, w/w) with HPC MF (10%, w/w) or HPMCAS-LG (10%, w/w) were prepared using a
co-rotating twin-screw extruder with a screw configuration showed in Figure 2. P-CO2 was
injected into zone 9 of the extruder or NaHCO3 was added (10% w/w) during the extrusion
process. In vitro dissolution studies (0.1 N hydrochloric acid medium) demonstrated that the
formulations floated on the medium because of their porosity and low density. Formulations
with NaHCO3 (F9, F10) showed better extended release potential than the counterparts with
P-CO2 (F7, F8). The in vitro drug release mechanism of the optimized formulation was found
to best fit with the first-order (R2=0.9686) and Higuchi models (R2=0.9614). Accelerated
stability studies demonstrated similar release profiles between fresh samples and stability
samples after 3 months storage. Altogether, the ACV floating gastro-retentive formulations
were successfully developed, which can prolong the gastric residence time to extend
therapeutic effects.

ii

DEDICATION

This thesis is dedicated to my dear parents, Mr. Guogang Zhang and Mrs. Hong Tian
and to everyone who helped me and guided me through my own times of stress and anxiety.
Also, I am grateful to my girlfriend, Sooyeon Chung, who supported me all the time.

iii

LIST OF ABBREVIATIONS AND SYMBOLS

ACV Acyclovir

P-CO2 Pressurized Carbon Dioxide

NaHCO3 sodium bicarbonate

DSC Differential Scanning Calorimetry

HME Hot-Melt Extrusion

SEM Scanning Electronic Microscopy

FTIR Fourier Transform Infrared

Hydroxypropyl cellulose HPC

Hydroxypropyl methylcellulose acetate succinate HPMCAS

iv

ACKNOWLEDGMENTS
I express my deepest appreciate to my advisor, Dr. Michael A. Repka for his
encouragement throughout the entire process. And my committee members, Dr. Chambliss,
and Dr. Eman Ashour who were more than generous with their expertise and precious time. I
want to thank Gauri and Mashan because I could not finish the whole project without the
assistance from them.
I would like to thank my postdoc Dr. Bandari for expertise and advice on my research.
Special thanks to Ms. King for her continued support.
Lastly, I am deeply thankful to all my colleagues and friends for their help, friendship
and spiritual support in my study and life.

v

TABLE OF CONTENTS
ABSTRACT............................................................................................................................... ii
DEDICATION .......................................................................................................................... iii
LIST OF ABBREVIATIONS AND SYMBOLS ................................................................... iv
ACKNOWLEDGMENTS ....................................................................................................... v
TABLE OF CONTENTS ........................................................................................................ vi
LIST OF TABLES ................................................................................................................ viii
LIST OF FIGURES ................................................................................................................ ix
INTRODUCTION ................................................................................................................... 1
MATERIAL AND METHODS ............................................................................................... 4
Materials ................................................................................................................................. 4
Methods.................................................................................................................................. 4
Formulations ....................................................................................................................... 4
Hot-melt extrusion process ................................................................................................. 5
Differential scanning calorimetry (DSC) ........................................................................... 6
UV- Visible spectrophotometric analysis ......................................................................... 7
Drug content ....................................................................................................................... 7
In vitro drug release ............................................................................................................ 7
Drug release Kinetics ......................................................................................................... 8
vi

Fourier transform infrared (FTIR) spectroscopy analysis .................................................. 8
Scanning electron microscopy (SEM) ................................................................................ 9
Stability tests ...................................................................................................................... 9
RESULTS AND DISCUSSION .............................................................................................. 10
Hot Melt Extrusion ............................................................................................................... 11
DSC analysis ...................................................................................................................... 13
Drug content studies ........................................................................................................... 15
In vitro drug release ............................................................................................................ 16
Drug release Kinetics ......................................................................................................... 19
FTIR analysis ....................................................................................................................... 20
SEM analysis ........................................................................................................................ 21
Stability tests ........................................................................................................................ 22
CONCLUSION ........................................................................................................................ 24
BIBLIOGRAPHY .................................................................................................................... 25
VITA ........................................................................................................................................ 29

vii

LIST OF TABLES
Table 1. Formulations of different polymers ............................................................................. 5
Table 2. Result of formulations ............................................................................................... 12
Table 3. In vitro release Kinetics of Acyclovir Gastro-Retentive Formulations ..................... 20
Table 4. Dissolution data of stage two of the initial and the 3-monthc ACV extrudates ........ 23

viii

LIST OF FIGURES
Figure 1. Schematic representation of the set-up for the combined HME/P-CO2 techniques;
Injection of P-CO2 at Zone 9 ..................................................................................................... 6
Figure 2. Thermo Fisher standard screw configuration ........................................................... 13
Figure 3. DSC thermograms of pure API, pure polymers, and acyclovir extrudates with
P-CO2 and addition of sodium bicarbonate ............................................................................. 14
Figure 4. Transformations of acyclovir ................................................................................... 15
Figure 5. Drug content of each formulation............................................................................. 16
Figure 6. Dissolution profile of stage one formulations .......................................................... 18
Figure 7. Dissolution profile of stage two formulations ........................................................ 18
Figure 8. FTIR spectra of the formulations, pure NaHCO3, and pure acyclovir .................... 21
Figure 9. FEM images of acyclovir extrudates with P-CO2 and the addition of sodium
bicarbonate. A and B: F7; C and D: F8; E and F: F9; G and H: F10....................................... 22
Figure 10. Drug content data of the initial ACV extrudates and the 3-month stability samples
stored at 40 °C/75% RH ......................................................................................................... 23

ix

1. INTRODUCTION
Oral dosage forms, one of the commonly used routes of administration, have the
following advantages: ease of dosing administration, patient compliance, and flexibility in
formulation. However, conventional oral preparations have some restrictions; some drugs are
absorbed in the upper part of the stomach or small intestine, possess short half-lives, and
quickly disappear from systemic circulation. Hence, to achieve adequate therapeutic activity,
frequent

administration

is

required

[1].

To

improve

such

circumstance,

oral

sustained-controlled release formulations, which can slowly release to the gastrointestinal
tract (GIT), should be developed to maintain effective systemic drug concentrations for long
periods [2]. The gastro-retentive drug delivery system can prolong the retention time of a
drug in the stomach, thereby extending its transport time throughout the gastrointestinal tract
and increasing the degree of drug absorption, ultimately improving the clinical efficacy [3].
Many approaches for developing such gastro retentive systems have been reported in the
literature, such as floating systems, muco-adhesion systems, swellable systems, high-density
systems, modified shape systems, or the simultaneous administration of pharmacological
agents that delay gastric emptying [4]. Based on current research, floating drug delivery
systems (FDDS) possess the greatest advantages among the different types of gastric
retention drug delivery systems [5]. This drug delivery system is suitable for drugs with an
absorption window in the stomach or upper small intestine [6]. FDDS can be divided into two
types: effervescent formulations and non-effervescent formulations [7]. In the present study,
non-effervescent FDDS was selected. In this system, hydrophilic polymers are used as a
matrix, which can swell to form a continuous gel layer that controls drug release from the
matrix [8].
1

In the pharmaceutical industry, solid dispersions are one of the most promising
strategies for improving the oral bioavailability of poorly water-soluble drugs. This strategy
can significantly increase bioavailability by reducing particle size, improving wetting, and
reducing agglomeration [9]. Processing technologies such as spray drying (SD), hot-melt
extrusion (HME), freeze-drying (FD), and supercritical fluid drying (SFD) can be employed
to prepare solid dispersions [10]. Among them, HME is one of the most promising processing
technologies. HME is the process of converting raw materials with a rotating screw under
controlled conditions (temperature, feed rate, and pressure) through a die, into a product of
uniform shape [11]. In addition to being widely used in the preparation of amorphous solid
dispersions, HME is also used in many other applications such as taste-masking, modified
drug release, and stabilization of an active pharmaceutical ingredient (API) [12]. There are
many advantages of using HME compared to conventional pharmaceutical processing
methods. For example, it is a solvent-free processing method for solid dispersions, the
equipment has a small carbon footprint, and it entails a fast-continuous manufacturing
process [13].
In recent years, the combination of carbon dioxide (CO2) and HME has attracted the
interest of researchers. CO2 is environmentally friendly, non-flammable, and has a low cost
[14]. According to the literature, pressurized CO2 (P-CO2) can be used as a foaming agent
[15]. Because of the expansion characteristics of P-CO2 on the extrusion die during the HME
process, the micro-morphology of the extrudate is transformed into a foam-like structure [16].
This morphological change could lead to a porous and low-density system, which causes the
floating of extrudates in the medium.
Acyclovir (ACV, 9-(2-hydroxyethoxymethyl) guanine), an antiviral drug that can
inhibit the action of viral DNA polymerase and DNA replication of different herpes virus
[17], is primarily used to treat herpes simplex virus type 1 and 2 (HSV-1 and HSV-2),
2

varicella-zoster virus, chickenpox, and shingles [18,19]. The molecular weight of acyclovir is
225.2, the melting point of acyclovir is 256℃, logP of acyclovir is -1.59, water solubility of
acyclovir is 1.2±0.07 mg/mL at 25°C, and the pKa of acyclovir is 2.34 and 9.23[20][21][22].
Although oral administration is the most convenient route for patients, oral absorption is not
satisfactory for many drugs. ACV has pharmacokinetic limitations. Its oral bioavailability is
10-20%; however, this decreases with an increase in dose[23]. Further, 80% of an oral dose is
not absorbed and can be detected in the feces. ACV has a relatively short elimination half-life
of 3 h; thus, the frequency of administration of ACV is high, up to five times per day, thereby
leading to patient incompliance [23]. ACV is soluble in acidic pH and is mainly absorbed
from the upper gastrointestinal tract when administered orally [23]. Experiments show that
the drug is only absorbed from the upper part of the gastrointestinal tract [24]. Thus, a
gastro-retentive sustained release formulation of ACV should be developed.
In the present study, we aimed to prepare ACV gastro-retentive formulations via
HME techniques using P-CO2 and sodium bicarbonate. A subsequent goal of this study was
to compare the products of P-CO2 versus sodium bicarbonate to derive an appropriate
approach for gastric retention; this will enable the establishment of a porous and low density
floating multi-particulate system that can prolong gastric residence time, reduce the number
of dosages, and improve bioavailability and therapeutic efficacy. Herein, hydroxypropyl
cellulose (HPC) EF, HPC MF, and hydroxypropyl methylcellulose acetate succinate
(HPMCAS) LG were used as the matrix polymers.

3

2. MATERIALS AND METHODS

2.1 Materials

ACV was purchased from Xinxiang Pharmaceutical Co. Ltd. (Xinxiang, Henan,
China). AquaSolve™ HPMCAS LG, KlucelTM EF, and KlucelTM MF were donated by
Ashland Specialty Ingredients (Wilmington, DE). Sodium bicarbonate (USP/NF standard)
was purchased from Spectrum Chemical Mfg. Corp (Gardena, CA, USA). CO2 was supplied
in gas cylinders (pure clean) by Airgas (Tupelo, MS). All other chemicals and reagents used
in the present study were of analytical grade.
2.2 Methods
2.2.1 Formulations

In this study, different formulations were investigated and separated into two different
stages (Table 1). The first stage (stage one) was to examine the effect of sodium bicarbonate
and P-CO2 on a single polymer. In this process, 6 formulations of a single polymer with 20%
w/w drug load were examined. The second stage (stage two) was based on the results of the
dissolution study; thus, a binary mixture of polymers was blended to achieve sustained
release of the drug. The physical mixture of the polymer and ACV (20% w/w) was uniformly
blended for 20 min using a V-shell blender (Maxiblend, Globe Pharm). Thereafter, it was fed
into the extruder.

4

Table 1.

ACV formulations.

Formulation ACV
(w/w)
F1
20%

Excipients (w/w)

Stage
1

Stage
2

F2

20%

80% HPC MF

F3

20%

80% HPMC-AS LG

F4

20%

70% HPC EF, 10% NaHCO3

P-CO2
(PSI)
100-2
50
150-3
00
150-3
00
-

F5

20%

70% HPC MF, 10% NaHCO3

-

F6

20%

70% HPMC-AS LG, 10% NaHCO3

-

F7

20%

70% HPC EF, 10% HPC MF

F8

20%

70% HPC EF, 10% HPMC-AS LG

F9

20%

60% HPC EF, 10% HPC MF, 10%NaHCO3

100-2
50
100-2
50
-

F10

20%

60% HPC EF 10% HPMC-AS LG 10% NaHCO3 -

80% HPC EF

2.2.2 Hot-melt extrusion process

The gastro-retentive formulations were prepared using HME techniques employing a
twin-screw extruder (16-mm Prism Euro Lab; Thermo Fisher Scientific, Waltham, MA). The
extruder is divided into 10-barrel areas next to the gravimetric feeder. This study used a
screw configuration consisting of four conveying zones and three mixing zones. For the
formulations F1，F2, F3, F7 and F8, pressurized CO2 was injected into the extruder using a
high-pressure regulator connected to flexible stainless-steel hose with armor casing. The
other end of the hose was connected to a four-way connection and fitted with a pressure
5

gauge, bleed valve, and check valve (ball type for a unidirectional flow of gas), with the latter
connected to an injection port at zone 9 (conveying zone) of the extruder（Figure 1）. The
regulator knob was used to regulate the P-CO2 flow rate[25]. For the other formulations F4,
F5, F6, F9 and F10, the uniformly blended physical mixture of polymer and ACV (20% w/w)
and sodium bicarbonate (10% w/w) was fed into the extruder using the volumetric feeder
without CO2. The temperature of the barrel was 140℃ with 100 rpm for both the approaches.

Figure 1. Schematic representation of the set-up for the combined HME/P-CO2 techniques;
Injection of P-CO2 at Zone 9.

2.2.3 Differential scanning calorimetry (DSC)

DSC (TA Instruments, New Castle, DE) was used to investigate the polymorphic and
thermal properties of the API, excipients, and extrudates. All samples were prepared in TA
aluminum pans and lids (Tzero) with an average sample weight of 5–7 mg. All samples were
kept at equilibrium via holding at a temperature of 25 °C followed by heating from 25 °C to
300 °C at a ramp rate of 10 °C/min under an inert nitrogen cell purge flow of 50 mL/min.

6

2.2.4 UV- Visible spectrophotometric analysis

UV- Visible spectrophotometric method was used (GENESYS 6 UV- Vis
spectrophotometer, Thermo Scientific, Madison WI, US) to determine the ACV
concentration at a wavelength of 252 nm[26]. The calibration curve was linear over the
concentration range of 2 to 18 μg/mL (R2 >0.9999).

2.2.5 Drug content

The extrudate was milled into a fine powder using a coffee blender. First, 50 mg of
each formulation was weighed and transferred into a 250-mL volumetric flask. Methanol (60
mL) and 0.1 N hydrochloric acid (190 mL) were then added to the flask and sonicated for 15
min. The samples were centrifuged, and the supernatant was diluted to the appropriate
concentration (40 times) and analyzed using a UV-Vis spectrophotometer at 252 nm.

2.2.6 In vitro drug release

In vitro drug release studies were conducted using a USP dissolution apparatus II
equipment (Hanson Research SR8plus station). Each experiment was carried out in triplicate
in 900 mL 0.1 N hydrochloric acid as a medium at 37±0.5 ℃ for 12 h. 2000mg of each
formulation was weighted and put in the medium. The paddle speed was set at 50 rpm.
Samples were analyzed at 0.5, 1, 2, 4, 6, 8, 10, and 12 h. Aliquots of 2 mL of dissolution
media were collected and an equivalent volume of fresh dissolution media was added. The
samples were filtered through 0.2-μm, 13 mm PTFE membrane filters (Whatman, Inc.,
Haverhill, MA, USA), diluted to the appropriate concentration (40 times) with dissolution
7

media, and analyzed using a UV-Vis spectrophotometer with the above method. The floating
ability of the formulations was observed during the dissolution study.

2.2.7 Drug release Kinetics

Mathematical models (first order, zero order and Higuchi) of drug dissolution were
used to assess the dissolution profiles [27,28].
Zero-order model:
𝑊𝑊0 − 𝑊𝑊𝑡𝑡 = 𝑘𝑘𝑘𝑘

(1)

Where Wt is the amount of drug released at time t, W0 is the initial concentration of drug at
time t=0, and k is the zero-order rate constant.
First-order model:
𝑙𝑙𝑙𝑙(𝑊𝑊𝑡𝑡 ∕ 𝑊𝑊0 ) = 𝑘𝑘1 𝑡𝑡

(2)

Where Wt is the amount of drug released at time t, W0 is the initial concentration of drug at
time t=0, and k1 is the first-order rate constant.
Higuchi model:
1

𝑊𝑊 = 𝑘𝑘𝑡𝑡 2

(3)

Where W is the amount of drug released at time t and k is the Higuchi dissolution constant.

2.2.8 Fourier transform infrared (FTIR) spectroscopy analysis

FTIR studies were conducted with an Agilent Cary 660 FTIR Spectrometer (Agilent
Technologies, Santa Clara, CA, USA) in the 4000–600 cm−1 spectral range. The bench top
ATR (Pike Technologies, Madison, WI, USA) was equipped with a single bounce
diamond-coated ZnSe internal reflection element. To study the interaction between the drug
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and polymer, a small amount of the extrudate powder was placed on top of the diamond
crystal and compressed with the MIRacle high-pressure Clamp.

2.2.9 Scanning electron microscopy (SEM)

Samples were mounted on aluminum stubs held with a carbon adhesive film, which
were coated using a Hummer® 6.2 sputtering system (Anatech Ltd., Battlecreek MI, USA) in
a nitrogen environment at 120 mm Hg and a current of 15 mA. The morphology of each
sample was observed using a scanning electron microscope operated at an accelerating
voltage from 1.0 kV to 5.0 kV (JEOL JSM-5600; JEOL, Inc., Peabody MA, USA).

2.2.10 Stability tests

A stability study of the stage two formulations was conducted at 40 °C and 75%
relative humidity, which are accelerated stability test conditions, for three months. All
formulations were stored in 20-mL clear glass scintillation vials. The samples were analyzed
at time zero and after 3 months. Drug content determination and dissolution testing were
performed and compared with the fresh samples. To compare the release profiles of the initial
and stability samples, a similarity factor (ƒ2) was calculated [29]. The equation for the
similarity factor is represented in Eqn. 4.
1

𝑛𝑛

𝑓𝑓2 = 50 𝑙𝑙𝑙𝑙𝑙𝑙 ��1 + 𝑛𝑛 �𝑛𝑛=1(𝑅𝑅𝑡𝑡 − 𝑇𝑇𝑡𝑡 )2 �

−0.5

× 100�

(4)

Where Rt and Tt are % dissolved for the initial sample and stability sample, respectively, at
each time point while n denotes the number of time points. If the f2 value of the two drug
release profiles is between 50 and 100, the initial and stable samples are considered similar
[30].
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3. RESULTS AND DISCUSSION

HPC and HPMC are commonly used as hydrophilic carrier materials in modified
release formulations. Both HPC and HPMC can swell to form a viscous hydrogel that
controls drug release from the matrix [31]. Additionally, because of the high melt viscosity of
HPMC, processing of HME generates high torque and requires a high temperature [31].
Further, injection of CO2 is difficult to achieve. HPC EF has a low molecular weight and low
melt viscosity, it’s easy to get the extrudates with P-CO2. Therefore, HPC EF was selected as
the primary polymer. However, because HPC EF dissolves very quickly to achieve extended
release, some secondary polymers were required to be added to delay drug dissolution.
HPMCAS is insoluble in acidic aqueous solutions. Therefore, addition of HPMCAS
can delay the dissolution of gastric floating tablets and gastro-retentive pellets. HPMCAS-LG
has a higher concentration of succinyl groups than other grades (MG and HG), which show
higher hydrophilicity [32]. Similarly, HPC MF has a higher molecular weight and viscosity;
thus, HPMCAS-LG and HPC MF were selected as secondary polymers.
The injection of CO2 during HME of a binary mixture of drug and polymer resulted in
the synthesis of a porous low-density foaming structure, with floating characteristics that
prolong the gastric residence time. After 50 °C, sodium bicarbonate gradually decomposes to
produce CO2, sodium carbonate, and water. Therefore, in the process of HME, the
formulation with sodium bicarbonate can be synthesized into a foamed strand. When exposed
to stomach acid, CO2 is generated by reaction with sodium carbonate, and sodium bicarbonate
with hydrochloric acid, which is entrapped in the polymer gel matrix to prolong buoyancy
10

[33]. CO2 has been investigated as a temporary plasticizer, which can both increase the free
volume between polymer chains and decrease chain entanglement, causing reduction in melt
viscosity and the glass transition temperature [32,34]. Therefore, sodium bicarbonate and
P-CO2 were selected as foaming agents to prepare a porous and low density floating
multi-particulate system.

3.1 Hot Melt Extrusion

All formulations were successful prepared with a Process 16 twin screw extruder
(Thermo Fisher Scientific) except F3 and F4 because of the high melt viscosity and high
molecular weight of HPC MF and HPMCAS-LG (Table 2). The Thermo Fisher standard
screw configuration (Figure 2), which consists of four conveying zones and three mixing
zones, was also employed. To achieve extrudability of materials during the extrusion process,
the extrusion temperature was set at 10-20 °C above the Tg of the polymer [32]. Further, HPC
EF, HPC MF, and HPMC-AS LG were selected as controlled release polymers, all of which
have a Tg near 120 °C. As sodium bicarbonate begins to dissociate at 110 °C, reaches its peak
at approximately 150 °C, and finishes below 170 °C, the optimum processing temperature
was selected as 140 °C to achieve the foaming effect of SBC. To ensure consistency of the
test parameters, the temperature of all formulations was optimized at 140 °C. The screw
speed of the extruder was set at 100 rpm, and barrel torque was controlled between 30% to
65%. In the processing of Formulation 6, the temperature was increased to 160 °C to reduce
the high motor torque and facilitate the ease of extrusion because of the high melt viscosity of
HPMC. During extrusion with P-CO2, the pressure was maintained between 150-250 psi.
When 4 or 6 zones were selected for CO2 injection, the back-pressure phenomenon was very
evident, ultimately spreading the materials out of the feeding zone. To avoid this spreading,
11

the injection zone was kept away from the feeding zone. Thus, the zone 9 was selected as the
injection zone of P-CO2. Extrudates of HPC MF or HPMC-AS LG (F2 and F3) with P-CO2
failed owing to the high molecular weight and high melt viscosity, which increased the
difficulty of CO2 penetration into the matrix. Other formulations successfully produced
foamy, porous extrudates.

Table 2. Result of formulations
Formulation

Stage one

Stage two

Result

F1

Successful

F2

Failed

F3

Failed

F4

Successful

F5

Successful

F6

Successful

F7

Successful

F8

Successful

F9

Successful

F10

Successful
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Figure 2. Thermo Fisher standard screw configuration

3.2 Differential scanning calorimetry (DSC)

A DSC image of pure API, pure polymers, and formulations in stage two is presented
in Figure 3. DSC thermograms of pure ACV revealed decomposition at 257 °C with onset at
249.5 °C. The transformations between different crystal structures of ACV are shown in
Figure 4. According to the literature, the commercial form of ACV is a 3:2 ACV/water
solvate, termed Form V. Upon heating, two transitions of Form V are formed. First, Form V
is dehydrated to Form III, which then changes to Form IV between 170 °C and 180 °C [35].
Hence, the small endothermic peak at approximately 177 °C is for the transformation of the
crystal form of ACV. Reports reveal that Form V of ACV has two overlapping peaks
between 148 °C and 179 °C [35], thereby aligning with the DSC image of pure ACV. In the
DSC thermogram for F9 and F10, both have an endothermic peak at approximately 170 °C.
The melting point of sodium bicarbonate is ~167 °C, indicating that there is residual sodium
bicarbonate in F9 and F10. The thermograms of F7 and F8 revealed peaks at ~250 °C, which
indicates that complete conversion of ACV in F7 and F8 into the amorphous state was not
achieved after HME coupled with P-CO2 processing. In contrast, in F9 and F10, the absence
13

of the peak indicated that F9 and F10 assumed an amorphous nature after HME with the
addition of sodium bicarbonate. This phenomenon may be caused by the formation of a
eutectic mixture of ACV and sodium bicarbonate. Eutectic mixtures tend to destroy
intermolecular forces (reduce changes in enthalpy) or increase the disorder generated during
melting (changes in entropy). As this leads to a reduction in melting temperature [36],
transformation of the drug into an amorphous state can be easily achieved. However, this
hypothesis should be further confirmed as it was not within the scope of the current study.

Figure 3. DSC thermograms of pure API, pure polymers, and acyclovir extrudates with
P-CO2 and addition of sodium bicarbonate.

14

Figure 4. Transformations of acyclovir.

3.3 Drug content

UV-Visible spectrophotometric analysis confirmed that the drug content of ACV in
all formulations is consistent with the theoretical value and it was within the range of 93.8–
102.5%, which confirmed that the ACV was uniformly distributed in the extrudates. All
results were listed in Figure5.

15

Figure 5. Drug content of each formulation

3.4 In vitro drug release

All formulations floated immediately and throughout the course of the dissolution
study, when placed in the dissolution media, without any lag time, thereby demonstrating
good buoyancy. In Figure 6, the formulations manufactured using the HPC EF polymer (F1,
F4) exhibited faster drug release than those with HPC MF (F5), HPMCAS-LG (F6), and the
combination of polymers. This is because HPC EF exhibited faster erosion than HPC MF and
HPMCAS-LG. At 1 h, the drug release rate was 60.4±3.04% and 51.6±5.5%; however, at 4 h,
the rate exceeded 90% in the F1 and F4 formulations, respectively. The ACV gastro-retentive
formulations of HPC EF were successfully prepared using HME with P-CO2 and the addition
of sodium bicarbonate. However, the release rate was too fast; thus, high viscosity polymers
were added as secondary polymers to achieve the sustained-release characteristics. The
16

dissolution profile of F5 and F6 demonstrated that HPC MF and HPMCAS-LG retarded drug
release. HPC MF has a high viscosity, which contributed to high gel layer density, thereby
retarding polymer dissolution [31]. HPMCAS-LG not only has a high melt viscosity [32], but
is also insoluble in acidic aqueous solution. Therefore, formulation F6 showed drug release of
74% after the 12-h dissolution test. Some pellets were also evident in the dissolution medium
after 12 h.
In the first hour, the dissolution rate of F7 and F8 was faster than that of F9 and F10
(Figure 7). This is because F7 and F8 have a higher porosity, which results in increased
surface area contact with the solvent. The surface area of the substance accessible to the
dissolution medium can affect the release rate [37].
The similarity factor (ƒ2) value of the F9 and F10 is 78.26. Both F9 and F10 gave
comparable dissolution profiles. So, there is no significance different between F9 and F10.
After 2 hours, F8 was found to exhibit a slower release than F7 as it had HPMCAS. However,
in the first 2-hour, higher release rate was achieved with F8 than with F7, which may be due
to the uneven application of pressure during the P-CO2, resulting in higher porosity for F8
than F7.

17

Figure 6. Dissolution profile of stage one formulations.

Figure 7. Dissolution profile of stage two formulations.
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3.5 Drug release Kinetics:

Effects of various formulation parameters are presented in Table 3. The correlation
coefficient (R2) of each formulation was used as an indicator of the best fitting for each of the
drug release models. The release mechanism for all formulations in this research could not be
attributed to a zero-order mechanism according to the release kinetics data. Based on the
correlation coefficient result, all formulations except F1 and F2, exhibited the best fit with the
first-order and Higuchi models. If the correlation coefficient of the Higuchi model is high, the
mechanism of drug release can be considered to be a diffusion-controlled release mechanism
[27]. Hence, all formulations, except F1 and F2, had diffusion mechanisms. F9, with in
combination with HPC EF, HPC MF, and SBC, had a similar correlation coefficient in the
Higuchi model to F5 in combination with HPC MF and SBC. F10, in combination with HPC
EF, HPMCAS-LG, and SBC, had a similar correlation coefficient in the Higuchi model to
F10, in combination with HPMCAS-LG and SBC. This finding demonstrates that viscosity of
HPC MF and HPMCAS-LG was responsible for controlling drug release. F4, in combination
with HPC EF and SBC, could not form a strong hydrogel around the pellets, indicating that
HPC EF has a lower viscosity. According to the dissolution profile and the dissolution
kinetics, F9 and F10 were considered the optimized formulations.
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Table 3.

In vitro release Kinetics of Acyclovir Gastro-Retentive Formulations

Formulation code
F1
F4
F5
F6
F7
F8
F9
F10

Zero-order
First-order
Correlation coefficient (R2)
0.5648
0.7807
0.6065
0.7059
0.8128
0.979
0.8484
0.9535
0.7396
0.9467
0.6447
0.9179
0.7983
0.9605
0.8278
0.9686

Higuchi
0.8024
0.8315
0.956
0.9804
0.9267
0.8625
0.9472
0.9614

3.6 Fourier transform infrared (FTIR) spectroscopy analysis

FTIR spectra of the API, polymer and formulations of stage two are presented in
figure 8. All HPC EF, HPC MF and HPMCAS-LG spectra showed a significant absorbance
peak at 1,046 cm-1, which represented C-O functional groups. The infrared spectra of ACV
showed a characteristic peak, for carbonyl, at 1650-1750 cm−1; the C=N stretching band
appears at 1631 cm−1 in the infrared spectra of ACV, the peak at 1150-1050 cm−1 indicated
C-O-C; the peak at 3437 cm-1 represents the aromatic secondary stretching vibration [38]. All
formulations showed evident peaks of the API and polymer in their formulations, which
indicated that there was no obvious chemical change between the API and polymers under
the studied processing conditions.
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Figure 8. FTIR spectra of the formulations, pure NaHCO3, and pure acyclovir

3.7 Scanning electron microscopy (SEM)

The SEM images of the stage two (F7, F8, F9, F10) processed extrudates are shown in
Figure 8. The microscopic morphology of the extrudates with P-CO2 or addition of sodium
bicarbonate was transformed to the foam-like framework owing to the expanded CO2, which
increased their inner surface area and porosity [25]. Extrudates with CO2 injection produced a
regular, round, and well-distributed porous structure, while extrudates with addition of
sodium bicarbonate did not display uniformity as CO2 release may not be consistent during
the extrusion process. Nonetheless, the extrudate with P-CO2 (F7, F8) had a better foam
structure than the extrudate with sodium bicarbonate (F9, F10). As a result, it can be inferred
that P-CO2 readily changes the morphology of the extrudate.
.
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Figure 8. SEM images of acyclovir extrudates with P-CO2 and the addition of sodium
bicarbonate. A and B: F7; C and D: F8; E and F: F9; G and H: F10.
3.8 Stability tests

Figure 9 shows the drug content results after stability testing under the conditions of
40 °C and 75% relative humidity for three months (accelerated stability test conditions). The
dissolution date showed in Tablet 4. The similarity factor (ƒ2) value of the dissolution study
was 64.46 for F7, 73.61 for F8, 65.67 for F9, and 73.38 for F10, which are all greater than 50.
Therefore, the stability test results indicated that the formulations showed no significant
change relative to the fresh samples regarding drug content and the dissolution study. Such
finding suggests that the developed formulations were stable over 3 months.
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Figure 10. Drug content data of the initial ACV extrudates and the 3-month stability samples
stored at 40 °C/75% RH.
Table 4. Dissolution data of stage two of the initial and the 3-monthc ACV extrudates
Drug

Formulations

release

F7

F8

F9

F10

(%)
Time (h)

Fresh

3 months

Fresh

3 months

Fresh

3 months

Fresh

3 months

0

0

0

0

0

0

0

0

0

0.5

27.10±1.41

32.24±2.23

37.60±5.66

44.06±3.32

20.27±1.38

20.63±2.10

20.01±0.52

24.83±2.17

1

37.94±1.01

46.25±1.98

58.10±2.16

59.45±5.53

33.08±2.70

27.98±5.17

32.57±1.78

33.22±1.99

2

54.55±1.10

57.24±1.60

69.97±1.24

75.54±2.77

52.36±4.59

41.80±6.56

50.83±2.30

47.21±3.02

4

68.89±1.72

76.99±2.12

82.98±3.64

82.01±0.55

79.86±3.64

76.94±3.95

73.40±3.82

77.11±3.53

6

81.83±0.42

86.40±0.92

89.14±3.30

89.01±1.93

90.20±3.30

86.20±4.56

89.34±1.33

86.38±2.22

8

91.62±0.09

92.40±0.33

93.48±4.02

93.37±1.39

93.43±4.02

90.40±3.89

95.85±0.46

92.67±3.48

10

91.27±1.92

93.12±1.73

94.98±2.85

93.20±2.30

98.15±2.85

95.99±2.32

98.23±0.90

96.01±1.23

12

90.75±1.03

93.93±1.33

94.68±3.67

92.67±0.94

97.63±3.67

95.47±0.82

97.13±2.37

93.90±3.82
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4. CONCLUSION

Based on the findings of this study, floating pellets can be used as a platform for
manufacturing a viable gastro-retentive formulation. In stage one, HPC MF or HPMC-AS LG
extrudates with sodium bicarbonate showed good buoyancy and extended release owing to
their high molecular weight and high melt viscosity. ACV gastro-retentive formulations of
HPC EF were successfully formulated using HME with P-CO2 and the addition of sodium
bicarbonate. In stage two, the ACV gastro-retentive formulations with a binary mixture of
polymers were successfully produced using HME with P-CO2 and the addition of sodium
bicarbonate. The formulations showed extended release for 8 hours with over 90% release of
the drug at the end of the dissolution study. Of all the formulations, F10 (20% ACV/60%
HPC EF/10% HPMC-AS LG /10% NaHCO3) was considered to be optimized formulation
based on its dissolution profile and dissolution kinetics. Compared to the formulations
containing sodium bicarbonate, the formulations with P-CO2 had a faster release owing to the
larger porosity. Compared to HPC EF, HPMCAS-LG showed better retardation of drug
release. The morphology of the extrudates was changed to a foam-like structure after P-CO2
injection and the addition of sodium bicarbonate. The P-CO2 extrudates showed uniform
pores relative to the sodium bicarbonate extrudates. This study demonstrated that the floating
pellets could be optimized and systematically developed as an extended release dosage form
by a continuous process using the HME technology.
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